Retatrutide is an investigational triple agonist — GLP-1, GIP and glucagon receptors at once — and it is not approved anywhere. Its Phase 2 trial arms ran up to 12 mg weekly; community protocols commonly report a far lower 1–3 mg weekly. Both are reported figures, and with GLP-1-class compounds the distinction matters: these are milligram-dosed drugs titrated over months under supervision, and miscalculated compounded doses have caused documented harm. This page does one job. The 10 mg and 20 mg vials arrive freeze-dried; the table below shows the concentration each water volume produces, and the calculator converts a chosen amount into a mark on an insulin syringe.
Open the Retatrutide calculator →| Concentration | 1 mL water | 2 mL water | 3 mL water | 5 mL water |
|---|---|---|---|---|
| 10 mg vial | 10,000 mcg/mL | 5,000 mcg/mL | 3,333 mcg/mL | 2,000 mcg/mL |
| 20 mg vial | 20,000 mcg/mL | 10,000 mcg/mL | 6,667 mcg/mL | 4,000 mcg/mL |
Concentration = vial contents ÷ water added. It is the same compound at every volume — more water only means a weaker solution, larger syringe marks that are easier to read, and a larger injection volume. On a standard U-100 insulin syringe, one unit is 0.01 mL at any barrel size.
Calculate a Retatrutide draw →Education only. This page is educational. Most compounds referenced are not approved for human use, and a "research use only" label carries no legal status of its own.
Arithmetic, not advice. The calculator performs unit-conversion arithmetic on figures you enter. It does not recommend a dose, a quantity, or a method of administration.
Reference ranges. Any amounts mentioned are values commonly reported in published research and community protocols, provided for reference only. Reported does not mean established, safe, or effective.
Not medical advice. Nothing here constitutes medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before beginning any protocol.